Loading...
OTCM
SCNLF
Market cap125mUSD
Nov 17, Last price  
1.06USD
1Q
684.02%
IPO
103.85%
Name

Scancell Holdings PLC

Chart & performance

D1W1MN
OTCM:SCNLF chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
-31.32%
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
-100.00%
2,176,000231000000000000005,271,00004,711,0000
Net income
-18m
L+45.87%
890,546-405,000-786,000-1,737,000-1,649,000557,058-1,902,000-2,223,000-2,415,000-2,583,000-3,545,000-4,195,000-5,627,000-5,506,000-15,477,000-2,065,000-11,936,000-5,859,000-12,272,000-17,901,000
CFO
-11m
L+72.91%
-1,059,000-1,314,000-1,777,000859,620-1,998,331-2,093,367-2,638,747-2,330,744-3,847,466-4,062,747-7,017,947-7,032,949-7,803,000-7,803,000-8,140,000-15,660,000-6,106,000-10,558,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Scancell Holdings plc is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative vaccine and antibody treatments. Its mission is to address significant unmet medical needs in both cancer and infectious diseases. The company's pipeline features several promising candidates, including SCIB1, currently in Phase II clinical trials for metastatic melanoma; SCIB2, aimed at non-small cell lung cancer; and Modi-1, which is undergoing Phase I/II studies for various indications such as head and neck, triple-negative breast, ovarian, and renal cancers. Additionally, Scancell is advancing Modi-2, a therapeutic agent specifically designed to target homocitrullinated cancer antigens. Its development efforts also encompass SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine engineered to provide protection against the SARS-CoV-2 virus. Founded in 1997, Scancell Holdings plc is headquartered in Oxford, United Kingdom.

Key people

Jean-Michel Cossery
Non-Executive Chairman of the Board · since 2023
Lindy Durrant
Chief Scientific Officer, Executive Director · since 2024
Phil L'Huillier
Chief Executive Officer, Executive Director · since 2024
Sathijeevan Nirmalananthan
Chief Financial Officer, Executive Director, Company Secretary · since 2024
Callum Scott
Head of Development · since 2024
Nermeen Varawalla
Chief Medical Officer · since 2024
Martin Diggle
Non-Executive Director · since 2019
Florian Reinaud
Non-Executive Director · since 2024
Susan Davies
Non-Executive Independent Director · since 2020
Non-Executive Independent Director · since 2019
IPO date
Jul 30, 2010
Employees
40
Domiciled in
GB
Incorporated in
GB
Headquarters & legal address
BELLHOUSE BUILDING
SANDERS ROAD
OXFORD SCIENCE PARK
OXFORD, OXF OX4 4GD
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑042025‑042024‑042023‑042022‑042021‑042020‑042019‑042018‑042017‑04
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT